Obstetrics & Gynecology Doctors in New Providence, NJ Accepting Medicare

5 Obstetrics & Gynecology doctors found. Showing 1 - 5

Dr. Joseph A Barresi, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 890 Mountain Ave, New Providence, NJ 07974 Phone: 908-277-8799    Fax: 908-608-2376

Dr. Alice B Gibbons, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 890 Mountain Ave, New Providence, NJ 07974 Phone: 908-277-8799    Fax: 908-608-2376

Jamieson Hart Greenwald, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 890 Mountain Ave, New Providence, NJ 07974 Phone: 908-277-8799

Christine Masterson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 890 Mountain Ave, New Providence, NJ 07974 Phone: 908-277-8799    Fax: 908-608-2376

Andrea Gibbons Hubschmann, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 890 Mountain Ave, New Providence, NJ 07974 Phone: 908-277-8799    Fax: 908-608-2376

News Archive

Incorporate other diseases into fight against AIDS

"The public and private sectors have achieved remarkable success in Africa in the battle against AIDS, and the question now is: Where do we go from here?" James Glassman, founding executive director of the George W. Bush Institute and former under secretary of state for public affairs and public diplomacy, writes in this Forbes opinion piece.

Prospect Medical Holdings completes registered exchange offer

Prospect Medical Holdings, Inc., today announced the completion of its exchange offer (the "Exchange Offer") for any and all of its outstanding 123/4% Senior Secured Notes, Series A, due 2014, which are not registered under the Securities Act of 1933 (the "Private Notes"), for an equal principal amount of its 123/4% Senior Secured Notes, Series B, due 2014, which have been registered under the Securities Act of 1933.

FDA grants Fast Track designation for AEterna Zentaris' perifosine

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma.

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st.

Read more Medical News

› Verified 7 days ago